<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24243" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Li-Fraumeni Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aedma</surname>
            <given-names>Surya K.</given-names>
          </name>
          <aff>KUMC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Surya Aedma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24243.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Li Fraumeni syndrome, also known as sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, is a rare inherited autosomal dominant disorder associated with abnormalities in TP53, a tumor suppressor protein gene. This activity illustrates the evaluation and management of Li Fraumeni syndrome and reviews the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the role of TP53 in the etiology of Li Fraumeni syndrome.</p></list-item><list-item><p>Explain the pathophysiology of Li Fraumeni syndrome.</p></list-item><list-item><p>Summarize the Chompret criteria in the evaluation of Li Fraumeni syndrome.</p></list-item><list-item><p>Review the importance of improving care coordination among the interprofessional team members to provide genetic counseling, medical care, and support services for patients affected by Li Fraumeni syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24243&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24243">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24243.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>In 1969, a remarkable cancer predisposition syndrome was reported by Li and Fraumeni.<xref ref-type="bibr" rid="article-24243.r1">[1]</xref>&#x000a0;Li-Fraumeni syndrome (LFS) is an inherited autosomal dominant disorder that is usually associated with abnormalities in the tumor suppressor protein P53 gene (TP53) located&#x000a0;on chromosome 17p13.<xref ref-type="bibr" rid="article-24243.r2">[2]</xref> It is also known as the sarcoma, breast, leukemia, and adrenal gland (SBLA) cancer syndrome. LFS variants include LFS1, LFS2, LFSL. LFS1&#x000a0;is associated with mutations in TP53, a tumor suppressor gene. LFS2&#x000a0;is associated with mutations in CHEK2 (checkpoint kinase two), also a tumor suppressor gene. LFS-L are individuals that do not have detectable mutations in P53.</p>
      </sec>
      <sec id="article-24243.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are three genes identified with Li-Fraumeni syndrome (LFS) Tp53 17p13, 1q23, and checkpoint kinase two genes CHEK2 locus at 22q12.1.<xref ref-type="bibr" rid="article-24243.r2">[2]</xref>&#x000a0;In these three genes, TP53 mutations are most common. P53 has many mechanisms of anticancer function; it plays a role in apoptosis, maintaining genomic stability, and inhibits angiogenesis. When DNA has sustained damage, it plays a role in the activation of DNA repair proteins. It can stop cell growth at the G1/S regulation point, which gives time for DNA repair proteins to fix the damage. If the damage is irreversible, it can trigger apoptosis. Checkpoint kinase 2 (Chek2) regulates the activities of P53.<xref ref-type="bibr" rid="article-24243.r3">[3]</xref><xref ref-type="bibr" rid="article-24243.r4">[4]</xref></p>
        <p>In TP53 mutations, one mutant allele&#x000a0;is&#x000a0;generally&#x000a0;inherited by individuals with Li-Fraumeni syndrome; the other allele&#x000a0;is&#x000a0;deleted or somatically mutated, which leads&#x000a0;to&#x000a0;loss of&#x000a0;functional&#x000a0;P53&#x000a0;protein.&#x000a0;Missense mutations are the most common to occur, usually in exons 5 to 8 which is the DNA binding region of the gene. When mutation testing is done targeting exons 5-8 (these are the usual targets for testing), nearly 70% of Li&#x02013;Fraumeni families meeting the required diagnostic criteria harbor P53 mutations. Partial loss of alleles presents with less family history, decreased numbers of tumors, and late disease onset.<xref ref-type="bibr" rid="article-24243.r5">[5]</xref></p>
        <p>Not all individuals with Li-Fraumeni syndrome have TP53 mutations. It also can&#x000a0;be due to an alteration in gene promoter which causes defective protein expression. It&#x000a0;may also be due&#x000a0;to new&#x000a0;mutations that have not been described.</p>
      </sec>
      <sec id="article-24243.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Li-Fraumeni (LFS) is a rare syndrome, as over 500 families with LFS&#x000a0;have been reported in the literature. There are likely over 1,000 multigenerational families worldwide with LFS. Children with a diagnosis of adrenocortical carcinoma have the highest occurrence of P53 mutations. The syndrome is also&#x000a0;associated&#x000a0;with childhood brain tumors, osteosarcomas, and rhabdomyosarcomas. Patients with multiple primary tumors have a high incidence of P53 mutations.<xref ref-type="bibr" rid="article-24243.r6">[6]</xref><xref ref-type="bibr" rid="article-24243.r7">[7]</xref></p>
        <p>Mutations in the core binding protein of TP53 have an increased risk of cancer. TP53 mutations have a high penetrance. The lifetime risk for women is 90 percent by age 60 years while in men the estimated lifetime risk is about 73 percent.<xref ref-type="bibr" rid="article-24243.r8">[8]</xref> While most hereditary family cancer syndromes involve specific tumor types, members of LFS are at risk for a wide range of malignancies, with particular&#x000a0;occurrences of breast cancer, bone sarcomas, and soft tissue sarcomas. Several other cancers have been reported but at a lower incidence in Li-Fraumeni syndrome.<xref ref-type="bibr" rid="article-24243.r9">[9]</xref></p>
        <p>The risk of developing multiple primary cancers is high in members of families with Li-Fraumeni syndrome compared to the general population. This excess risk mainly involves cancers characteristic of LFS, this&#x000a0;risk&#x000a0;is further increased in survivors&#x000a0;of childhood cancers, and these patients require close monitoring for early cancer signs.<xref ref-type="bibr" rid="article-24243.r10">[10]</xref></p>
        <p>Patients with&#x000a0;LFS&#x000a0;are&#x000a0;successfully treated during the initial cancer occurrence. However, radiation therapy should be avoided, when possible, due to several case reports and preclinical evidence showing an increased risk of radiation-induced cancers in these patients.<xref ref-type="bibr" rid="article-24243.r11">[11]</xref> Li-Fraumeni patients are at a high risk of developing a second primary malignancy.<xref ref-type="bibr" rid="article-24243.r12">[12]</xref></p>
      </sec>
      <sec id="article-24243.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Li-Fraumeni syndrome (LFS) occurs due to germ-line mutations in TP53. TP53 is a tumor suppressor gene, which&#x000a0;is located on band 17p13.1, which codes for a 53-kD nuclear protein transcription factor that has important regulatory control over cell proliferation and homeostasis, specifically apoptosis, DNA repair, and cell cycle. Mutations can arise in one of the parent's germ cells, de novo during embryogenesis, or can be inherited. Changes in P53 function results from either increased or aberrant protein function or loss of function of wild-type P53. Most&#x000a0;Li-Fraumeni syndrome TP53 mutations occur as missense point mutations in a hot-spot region of exons 5-8.<xref ref-type="bibr" rid="article-24243.r13">[13]</xref>&#x000a0;This&#x000a0;is the gene portion that codes for the core DNA-binding domain of the protein. This kind of mutation leads to stable but inactive protein, which accumulates in the nucleus of tumor cells. Any mutation like frameshift, nonsense and splice-site can also be present but do not lead to the accumulation of p53 protein.</p>
        <p>The cell loses protection against genetic alterations when P53 mutations occur. Ubiquitin ligase HDM2 and P53 interact with E3 and E4 proteins, which induce polyubiquitination and degradation of P53,&#x000a0;which prevents apoptosis.<xref ref-type="bibr" rid="article-24243.r14">[14]</xref><xref ref-type="bibr" rid="article-24243.r15">[15]</xref>&#x000a0;They are also associated with the overexpression of UBE4B and with the amplification of these genes in brain tumors. The absence of P53 mutations in some families indicates that P53 protein may undergo posttranslational modifications, or other genes may&#x000a0;be involved. Genetic copy number variation, used as an indicator of genetic instability, are higher in patients with germline TP53 mutations than in healthy individuals.</p>
        <p>
<bold>Mutations Associated with Younger Age of Onset in Li-Fraumeni Syndrome</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Short telomeres</p>
          </list-item>
          <list-item>
            <p>Genetic modifiers, including the MDM2-SNP309 polymorphism, and genetic anticipation</p>
          </list-item>
          <list-item>
            <p>P53-related cancers, usually breast cancer, soft tissue sarcoma, osteosarcoma (bone cancer), leukemia, brain tumors, adrenocortical carcinoma (cancer of the adrenal glands), and other cancers<xref ref-type="bibr" rid="article-24243.r16">[16]</xref><xref ref-type="bibr" rid="article-24243.r17">[17]</xref><xref ref-type="bibr" rid="article-24243.r18">[18]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24243.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The family history of cancer, young age at initial diagnosis, and multiple malignancies suggest cancer syndromes that are hereditary. Patients should be informed adequately about all the signs and symptoms of cancer. They must be counseled to consult whenever they have any unusual signs or symptoms related to cancer. A complete family history of multiple generations is very important&#x000a0;due to a significant increase in cancer risk within families.<xref ref-type="bibr" rid="article-24243.r19">[19]</xref> The history should include screening for multiple tumor types especially sarcomas, breast, leukemia, and adrenocortical tumors.<xref ref-type="bibr" rid="article-24243.r20">[20]</xref> Sometimes risk becomes evident only after several years, so it is very important to update the family history regularly.&#x000a0;Obtaining a thorough family history can be difficult, but it is an important part of evaluating every child diagnosed with an early malignancy. History should emphasize all cancers in the Li-Fraumeni syndrome spectrum.<xref ref-type="bibr" rid="article-24243.r21">[21]</xref></p>
        <p>No specific physical findings&#x000a0;are seen in individuals affected by Li-Fraumeni syndrome that differ from the findings related to specific cancers.&#x000a0;Physical findings to watch for in specific cancers include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neurologic features&#x000a0;like seizures, vomiting, headaches, and gait changes related to brain cancers</p>
          </list-item>
          <list-item>
            <p>A breast lump in breast cancer</p>
          </list-item>
          <list-item>
            <p>Soft-tissue mass or a bone-related mass in soft tissue sarcoma or bone sarcoma</p>
          </list-item>
          <list-item>
            <p>Pancytopenia, fatigue, fever, weight loss, loss of appetite, swollen lymph nodes, bleeding gums, and infections in acute leukemia</p>
          </list-item>
          <list-item>
            <p>Virilization including prepubertal genital hair, increased penile size, clitoromegaly, deep voice associated with an abdominal mass in adrenal cortical carcinoma<xref ref-type="bibr" rid="article-24243.r19">[19]</xref><xref ref-type="bibr" rid="article-24243.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>An annual&#x000a0;physical examination should be performed, including breast, skin, and neurological assessments.</p>
      </sec>
      <sec id="article-24243.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Initially, the diagnosis of Li-Fraumeni&#x000a0;was done using clinical criteria based on signs and symptoms the patient and family have. With advanced genetic testing, patients can now know if they carry a copy of the TP53 tumor mutation before showing any signs of LFS. Genetic testing for TP53 mutations is very important. It is important&#x000a0;to offer genetic counseling and testing to all relatives at risk of having a familial TP53 pathogenic variant. Genetic testing only detects approximately 70% to 75% of cases. Genetic counseling&#x000a0;must&#x000a0;be done to consider&#x000a0;genetic testing,&#x000a0;and if it concludes that a patient is carrying a copy of TP53 mutations,&#x000a0;the patient must&#x000a0;be counseled about surveillance and continuously&#x000a0;screened for LFS related types of cancer.<xref ref-type="bibr" rid="article-24243.r23">[23]</xref></p>
        <p>The decision to do genetic&#x000a0;counseling&#x000a0;and TP53 mutation testing&#x000a0;should be considered&#x000a0;for the following patients:</p>
        <p>
<bold>Diagnostic Criteria</bold>
</p>
        <p><bold>Classic Li-Fraumeni syndrome -&#x000a0;</bold>&#x000a0;It is&#x000a0;diagnosed&#x000a0;when the person has all the following criteria:<xref ref-type="bibr" rid="article-24243.r24">[24]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>A sarcoma diagnosed before age 45.</p>
          </list-item>
          <list-item>
            <p>A first-degree relative, parent, sibling, or child with any cancer before age 45.</p>
          </list-item>
          <list-item>
            <p>Any cancer before age 45 or a sarcoma at any age in first-degree or second-degree relative (grandparent, aunt/uncle, niece/nephew, or grandchild).</p>
          </list-item>
        </list>
        <p>
<bold>Chompret Criteria</bold>
<xref ref-type="bibr" rid="article-24243.r25">[25]</xref>
</p>
        <p>This includes brain tumor, adrenocortical cancer, breast cancer in the proband, and also has a lower age cutoff of &#x0003c;31 years. Consider a diagnosis of LFS for anyone with a personal and family history that meets one of the following three criteria.</p>
        <list list-type="bullet">
          <list-item>
            <p>A tumor belonging to the LFS spectrum before the age of 46. This includes any of these diseases: premenopausal breast cancer, soft tissue sarcoma, osteosarcoma, adrenal cortical tumor, brain tumor, leukemia, lung cancer.<bold>AND</bold></p>
          </list-item>
          <list-item>
            <p>At least one first- or second-degree relative with an LFS tumor before age 56 years or multiple tumors, except for breast cancer if the proband has breast cancer.</p>
          </list-item>
          <list-item>
            <p>A person with multiple tumors, except&#x000a0;when two&#x000a0;belong to the LFS tumor spectrum with the first occurring before age 46.</p>
          </list-item>
          <list-item>
            <p>A person who is diagnosed with adrenocortical carcinoma or choroid plexus tumor, irrespective of family history.</p>
          </list-item>
        </list>
        <p>Li-Fraumeni-like syndrome (LFL) is another term for families who do not meet the set classic criteria.</p>
        <p>
<bold>LFL-1, Birch Definition</bold>
<xref ref-type="bibr" rid="article-24243.r26">[26]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A person diagnosed with any brain tumor,&#x000a0;adrenocortical tumor, sarcoma, breast cancer&#x000a0;before age 45<bold>AND</bold></p>
          </list-item>
          <list-item>
            <p>A typical LFS cancer in a first or second-degree relative&#x000a0;at any age.<bold>AND</bold></p>
          </list-item>
          <list-item>
            <p>A first-degree or second-degree relative with any cancer before age 60.</p>
          </list-item>
        </list>
        <p>
<bold>LFL-2, ELES Criteria</bold>
<xref ref-type="bibr" rid="article-24243.r26">[26]</xref>
</p>
        <p>Two relatives (first-degree or second-degree) diagnosed with a typical LFS cancer at any age.</p>
        <list list-type="bullet">
          <list-item>
            <p>Individuals who have either classical criteria for LFS or the Chompret criteria or who have other combinations of cancer and family history that put them at risk for LFS or LFL syndrome, but in whom there is no known mutation in the family. Negative test results do not rule out LFS and these patients should be managed as if they have LFS.</p>
          </list-item>
          <list-item>
            <p>Women with early-onset breast cancer (less than 31 years) and without a detectable breast cancer gene 1 (BRCA1) or 2 (BRCA2) mutation. It increases the index of suspicion for Li-Fraumeni syndrome if there is a family history of sarcoma, brain tumor, or adrenocortical carcinoma. A negative result in these individuals does not rule out LFS.<xref ref-type="bibr" rid="article-24243.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with a family history of known TP53 mutation to test for the known mutation. A negative test in these individuals rules out LFS. Those who choose not to undergo testing should be managed as if they harbor the&#x000a0;TP53&#x000a0;mutation, at least until 50 years of age.</p>
          </list-item>
        </list>
        <p>Individuals with some cancers irrespective of age or family history should undergo genetic testing for TP53 deleterious gene mutations. These include a) adrenocortical carcinoma b) choroid plexus carcinoma at any age c) rhabdomyosarcoma before age three years d) osteosarcoma before age ten years e) childhood sarcoma (except Ewing sarcoma).<xref ref-type="bibr" rid="article-24243.r28">[28]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Consider prenatal testing for at-risk pregnancies in situations where a specific TP53 mutation has been identified.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Cancer Surveillance</bold>
</p>
        <p>Cancer surveillance&#x000a0;is required for individuals who&#x000a0;are at risk based on the history of LFS malignancy, the patient with known&#x000a0;TP53 tumor mutation, or those with increased risk in a family with LFS but without an identifiable mutation or who have not undergone mutation testing.<xref ref-type="bibr" rid="article-24243.r12">[12]</xref><xref ref-type="bibr" rid="article-24243.r29">[29]</xref><xref ref-type="bibr" rid="article-24243.r30">[30]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Complete annual physical examination and medical evaluation for unexplained symptoms</p>
          </list-item>
          <list-item>
            <p>Whole-body magnetic resonance imaging (WBMRI) annually</p>
          </list-item>
          <list-item>
            <p>Abdominal and pelvic ultrasound (US) every 3 to 4 months in children and annually in the adult</p>
          </list-item>
          <list-item>
            <p>Biochemical markers for adrenocortical functions</p>
          </list-item>
          <list-item>
            <p>Blood tests every 4 months (complete blood count, lactate dehydrogenase, and erythrocyte sedimentation rate)</p>
          </list-item>
          <list-item>
            <p>Breast cancer monitoring - breast self-examination monthly, biannual clinical breast examination with a healthcare provider, and annual breast imaging beginning at age 20 to 25 years (preferably MRI breast due to radiation&#x000a0;exposure from mammography)</p>
          </list-item>
          <list-item>
            <p>Colonoscopy every 2 to 5 years, beginning at age 25 to 30 or 5 years before the earliest known colon cancer in the family</p>
          </list-item>
          <list-item>
            <p>Blood test for biochemical markers and brain MRI as per Toronto protocol</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24243.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is currently&#x000a0;no procedure or treatment option to repair mutations in the P53 gene as P53 is not a drug target yet. In general, radiation therapy should be avoided in patients with Li-Fraumeni syndrome&#x000a0;as individuals are at high risk of radiation-induced secondary cancers. Similarly, exposure to computed tomography (CT) scans or X-rays should be avoided.<xref ref-type="bibr" rid="article-24243.r31">[31]</xref> Li-Fraumeni syndrome is a&#x000a0;complex syndrome with many implications for individuals and their families, so it is suggested patients with&#x000a0;LFS&#x000a0;or suspected&#x000a0;LFS&#x000a0;consult with a physician or health care system that has experience&#x000a0;in treating patients with Li-Fraumeni syndrome and providing medical care, genetic counseling, and special support services.<xref ref-type="bibr" rid="article-24243.r19">[19]</xref><xref ref-type="bibr" rid="article-24243.r32">[32]</xref></p>
        <p>No evidence suggests that individuals with LFS diagnosed with cancers should be treated uniquely from other patients with the same cancer. However, in breast cancer, complete mastectomy rather than lumpectomy which is usually&#x000a0;followed by radiation therapy is generally preferred because of the risks of second breast cancers or radiation-induced neoplasms.<xref ref-type="bibr" rid="article-24243.r33">[33]</xref><xref ref-type="bibr" rid="article-24243.r34">[34]</xref> Physicians should discuss the need for risk-reducing mastectomy; it must&#x000a0;be considered case-by-case, depending on the degree of&#x000a0;cancer risk and reconstructive options.</p>
        <p>Li-Fraumeni syndrome patients are prone to anxiety, depression, and clinically relevant distress. Psychological monitoring is&#x000a0;recommended and providing support is very important.</p>
      </sec>
      <sec id="article-24243.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Hereditary breast and ovarian cancer syndrome (HBOC)</p>
          </list-item>
          <list-item>
            <p>Lynch syndrome</p>
          </list-item>
          <list-item>
            <p>Multiple endocrine neoplasia<xref ref-type="bibr" rid="article-24243.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24243.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>There is no difference in the treatment of cancers in LFS and other cancers that occur sporadically. Advancement in the treatment of childhood cancers has increased the long-term survival for most children. Usual complications in survivors include second&#x000a0;primary malignancies, which mostly occur within 6 to 12 years after the first cancer.<xref ref-type="bibr" rid="article-24243.r36">[36]</xref><xref ref-type="bibr" rid="article-24243.r37">[37]</xref></p>
        <p>A second cancer may occur due to genetic predispositions such as constitutional&#x000a0;TP53&#x000a0;mutations. The risk for a second cancer increases with younger age at diagnosis of first cancer. Second cancer risk increases with radiation exposure,&#x000a0;so these individuals should avoid or minimize exposure to diagnostic and therapeutic radiation when possible. They have a predilection for developing subsequent primary tumors (especially sarcomas) in prior radiation fields.<xref ref-type="bibr" rid="article-24243.r7">[7]</xref><xref ref-type="bibr" rid="article-24243.r38">[38]</xref></p>
        <p>The cumulative probability of a person affected by LFS developing a second cancer is close to 60% at 30 years after developing the first cancer.</p>
      </sec>
      <sec id="article-24243.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Individuals with Li-Fraumeni syndrome can become resistant to chemotherapy. The risk of other primary cancers is increased if a germline mutation has occurred. There is evidence that a&#x000a0;TP53&#x000a0;genetic mutation can cause a patient to have an increased sensitivity to ionizing radiation. Individuals with germline&#x000a0;TP53&#x000a0;mutations should avoid or minimize exposure to diagnostic and therapeutic radiation when possible.<xref ref-type="bibr" rid="article-24243.r39">[39]</xref></p>
      </sec>
      <sec id="article-24243.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Referral to a genetic counselor is recommended to obtain a detailed family history, genetic counseling, discuss risks of cancer, and plan for cancer screening.<xref ref-type="bibr" rid="article-24243.r40">[40]</xref><xref ref-type="bibr" rid="article-24243.r41">[41]</xref><xref ref-type="bibr" rid="article-24243.r42">[42]</xref></p>
      </sec>
      <sec id="article-24243.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Parents and patients should be informed adequately about all the signs and symptoms of cancer. They must be counseled to&#x000a0;seek care whenever they have any unusual signs or symptoms that may be related to a cancer. Patients should&#x000a0;be trained&#x000a0;to perform a breast self-examination regularly every month, starting at age 18 years. Psychological monitoring is very important as these patients can develop anxiety or depression.</p>
      </sec>
      <sec id="article-24243.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of patients with Li-Fraumeni syndrome is best accomplished with an interprofessional team approach involving a geneticist, internist, oncologist, psychiatrist,&#x000a0;and radiologist. Li-Fraumeni syndrome patients are prone to anxiety, depression, and clinically relevant distress. Psychological monitoring by an interprofessional&#x000a0;team of oncology specialty nurses and oncologists is important and providing support is very important for good outcomes. [Level 5]</p>
      </sec>
      <sec id="article-24243.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24243&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24243">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/li-fraumeni-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24243">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24243/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24243">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24243.s16">
        <title>References</title>
        <ref id="article-24243.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ili&#x00107;</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kiralj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Markov</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mijatov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mijatov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vu&#x0010d;kovi&#x00107;</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Li-Fraumeni syndrome: a case report.</article-title>
            <source>Vojnosanit Pregl</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>71</volume>
            <issue>12</issue>
            <fpage>1159</fpage>
            <page-range>1159-62</page-range>
            <pub-id pub-id-type="pmid">25639008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fortuno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Spurdle</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.</article-title>
            <source>Hum Mutat</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>39</volume>
            <issue>12</issue>
            <fpage>1764</fpage>
            <page-range>1764-1773</page-range>
            <pub-id pub-id-type="pmid">30240537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doyle</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>A novel p.Gly187Arg TP53 variant appears to result in Li-Fraumeni syndrome.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-207</page-range>
            <pub-id pub-id-type="pmid">30239254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Vasudeva</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Munshi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies.</article-title>
            <source>Curr Pharm Des</source>
            <year>2018</year>
            <volume>24</volume>
            <issue>30</issue>
            <fpage>3566</fpage>
            <page-range>3566-3575</page-range>
            <pub-id pub-id-type="pmid">30255744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shibata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Press</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Clonal analysis of bilateral breast cancer.</article-title>
            <source>Clin Cancer Res</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>743</fpage>
            <page-range>743-8</page-range>
            <pub-id pub-id-type="pmid">9816225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salem</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hofherr</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doros</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smpokou</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Childhood Rhabdomyosarcoma in Association With a RASopathy Clinical Phenotype and Mosaic Germline SOS1 Duplication.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>e278</fpage>
            <page-range>e278-e282</page-range>
            <pub-id pub-id-type="pmid">27258033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mai</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Best</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>DeCastro</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Khincha</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Loud</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Bremer</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.</article-title>
            <source>Cancer</source>
            <year>2016</year>
            <month>Dec</month>
            <day>01</day>
            <volume>122</volume>
            <issue>23</issue>
            <fpage>3673</fpage>
            <page-range>3673-3681</page-range>
            <pub-id pub-id-type="pmid">27496084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rana</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>LaDuca</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McFarland</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dalton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Speare</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dolinsky</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>110</volume>
            <issue>8</issue>
            <fpage>863</fpage>
            <page-range>863-870</page-range>
            <pub-id pub-id-type="pmid">29529297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>McComb</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Osborn</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Wolpert</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wszolek</surname>
                <given-names>ZK</given-names>
              </name>
              <name>
                <surname>Sidransky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome.</article-title>
            <source>Cancer</source>
            <year>2000</year>
            <month>Jan</month>
            <day>15</day>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>433</fpage>
            <page-range>433-9</page-range>
            <pub-id pub-id-type="pmid">10640978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Neill</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Jagannathan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kamihara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nibecker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Itriago-Araujo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Masciari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barreto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Diller</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29077256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbosa</surname>
                <given-names>OV</given-names>
              </name>
              <name>
                <surname>Reiriz</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Boff</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Angiosarcoma in previously irradiated breast in patient with Li-Fraumeni syndrome. A case report.</article-title>
            <source>Sao Paulo Med J</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>133</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-3</page-range>
            <pub-id pub-id-type="pmid">25271877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shore</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Druker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gallinger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Naumer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kohlmann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Novokmet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabori</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Tijerin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schiffman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Malkin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>1295</fpage>
            <page-range>1295-305</page-range>
            <pub-id pub-id-type="pmid">27501770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zerdoumi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lanos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flaman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bougeard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Frebourg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tournier</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.</article-title>
            <source>Hum Mol Genet</source>
            <year>2017</year>
            <month>Jul</month>
            <day>15</day>
            <volume>26</volume>
            <issue>14</issue>
            <fpage>2591</fpage>
            <page-range>2591-2602</page-range>
            <pub-id pub-id-type="pmid">28369373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patnaik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>QE</given-names>
              </name>
              <name>
                <surname>El-Mahdy</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Praetorius-Ibba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>The ubiquitin-proteasome system regulates p53-mediated transcription at p21waf1 promoter.</article-title>
            <source>Oncogene</source>
            <year>2007</year>
            <month>Jun</month>
            <day>21</day>
            <volume>26</volume>
            <issue>29</issue>
            <fpage>4199</fpage>
            <page-range>4199-208</page-range>
            <pub-id pub-id-type="pmid">17224908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prives</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The p53 tumor suppressor protein: meeting review.</article-title>
            <source>Genes Dev</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-34</page-range>
            <pub-id pub-id-type="pmid">8096197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabori</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Nanda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Druker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malkin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome.</article-title>
            <source>Cancer Res</source>
            <year>2007</year>
            <month>Feb</month>
            <day>15</day>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>1415</fpage>
            <page-range>1415-8</page-range>
            <pub-id pub-id-type="pmid">17308077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zawlik</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kita</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vaccarella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mittelbronn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Franceschi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ohgaki</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas.</article-title>
            <source>Brain Pathol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-94</page-range>
            <pub-id pub-id-type="pmid">18462472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Talseth</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Meldrum</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Suchy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kurzawski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lubinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>MDM2 SNP309 T&#x0003e;G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.</article-title>
            <source>Int J Cancer</source>
            <year>2007</year>
            <month>Feb</month>
            <day>01</day>
            <volume>120</volume>
            <issue>3</issue>
            <fpage>563</fpage>
            <page-range>563-5</page-range>
            <pub-id pub-id-type="pmid">17096342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakhuizen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Velthuizen</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Stehouwer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bleiker</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ausems</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Genetic counselling of young women with breast cancer for Li-Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals.</article-title>
            <source>Fam Cancer</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-239</page-range>
            <pub-id pub-id-type="pmid">30238178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greer</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Imaging of cancer predisposition syndromes.</article-title>
            <source>Pediatr Radiol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>9</issue>
            <fpage>1364</fpage>
            <page-range>1364-1375</page-range>
            <pub-id pub-id-type="pmid">30078044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adeyanju</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ilori</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Multiple primary tumors.</article-title>
            <source>Niger J Clin Pract</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1346</fpage>
            <page-range>1346-1349</page-range>
            <pub-id pub-id-type="pmid">29192643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giavedoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ririe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carrera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malvehy</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>09</day>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>720</fpage>
            <page-range>720-723</page-range>
            <pub-id pub-id-type="pmid">28218344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Phelps</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tulpule</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nicolaides</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Apr</month>
            <day>24</day>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>e2527</fpage>
            <pub-id pub-id-type="pmid">29946497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guha</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Malkin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Inherited <italic>TP53</italic> Mutations and the Li-Fraumeni Syndrome.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2017</year>
            <month>Apr</month>
            <day>03</day>
            <volume>7</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">28270529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weitzel</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Nehoray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Van Tongeren</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>LaDuca</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Blazer</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Slavin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Facmg</surname>
                <given-names>DABMD</given-names>
              </name>
              <name>
                <surname>Pesaran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rybak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Niell-Swiller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dolinsky</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gau</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Speare</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jasperson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Somatic TP53 variants frequently confound germ-line testing results.</article-title>
            <source>Genet Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>809</fpage>
            <page-range>809-816</page-range>
            <pub-id pub-id-type="pmid">29189820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Shea</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berkley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giffney</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Donovan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Next generation sequencing is informing phenotype: a TP53 example.</article-title>
            <source>Fam Cancer</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>123</fpage>
            <page-range>123-128</page-range>
            <pub-id pub-id-type="pmid">28509937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penkert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schlegelberger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Steinemann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gadzicki</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways.</article-title>
            <source>Fam Cancer</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>601</fpage>
            <page-range>601-6</page-range>
            <pub-id pub-id-type="pmid">22864638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petr</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Else</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Adrenocortical carcinoma (ACC): When and why should we consider germline testing?</article-title>
            <source>Presse Med</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>47</volume>
            <issue>7-8 Pt 2</issue>
            <fpage>e119</fpage>
            <page-range>e119-e125</page-range>
            <pub-id pub-id-type="pmid">30104051</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wakefield</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Vetsch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Families' and health care professionals' attitudes towards Li-Fraumeni syndrome testing in children: A systematic review.</article-title>
            <source>Clin Genet</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>140</fpage>
            <page-range>140-150</page-range>
            <pub-id pub-id-type="pmid">30191952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mai</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Khincha</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Loud</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>DeCastro</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bremer</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Bluemke</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Malayeri</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.</article-title>
            <source>JAMA Oncol</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>3</volume>
            <issue>12</issue>
            <fpage>1640</fpage>
            <page-range>1640-1645</page-range>
            <pub-id pub-id-type="pmid">28772286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heymann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Delaloge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rahal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caron</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Frebourg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barreau</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pachet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mathieu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Marsiglia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bourgier</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome.</article-title>
            <source>Radiat Oncol</source>
            <year>2010</year>
            <month>Nov</month>
            <day>08</day>
            <volume>5</volume>
            <fpage>104</fpage>
            <pub-id pub-id-type="pmid">21059199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brzosowicz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Valladares</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wiesner</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Laronga</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Identification and Management of <italic>TP53</italic> Gene Carriers Detected Through Multigene Panel Testing.</article-title>
            <source>South Med J</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>110</volume>
            <issue>10</issue>
            <fpage>643</fpage>
            <page-range>643-648</page-range>
            <pub-id pub-id-type="pmid">28973705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tischkowitz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical implications of germline mutations in breast cancer: TP53.</article-title>
            <source>Breast Cancer Res Treat</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>167</volume>
            <issue>2</issue>
            <fpage>417</fpage>
            <page-range>417-423</page-range>
            <pub-id pub-id-type="pmid">29039119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pederson</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Padia</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grobmyer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Managing patients at genetic risk of breast cancer.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>83</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-206</page-range>
            <pub-id pub-id-type="pmid">26974991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Singh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mulji</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Multiple Endocrine Neoplasia Type 1</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">30725665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McEvoy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robison</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Manley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yock</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Konopka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>e473</fpage>
            <page-range>e473-e475</page-range>
            <pub-id pub-id-type="pmid">28859040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jhaveri</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lovick</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zuckerman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Deshpande</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rath</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hofstatter</surname>
                <given-names>EW</given-names>
              </name>
            </person-group>
            <article-title>The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report.</article-title>
            <source>Yale J Biol Med</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-5</page-range>
            <pub-id pub-id-type="pmid">26029016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valdez</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ogg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gattuso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alderfer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zelley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Mandrell</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Nichols</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Parent-child communication surrounding genetic testing for Li-Fraumeni syndrome: Living under the cloud of cancer.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>65</volume>
            <issue>11</issue>
            <fpage>e27350</fpage>
            <pub-id pub-id-type="pmid">30009566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potapov</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Abdilatipov</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Okhlopkov</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Gavrilov</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Zakharova</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Goryaynov</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kobyakov</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Absalyamova</surname>
                <given-names>OV</given-names>
              </name>
              <name>
                <surname>Kravchuk</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kulikov</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Shugay</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Nikitin</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Batalov</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Shelygin</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Lyubchenko</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Aliev</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Spallone</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Li-Fraumeni syndrome in a patient with multiple anaplastic oligodendrogliomas of the brain (a case report and literature review)].</article-title>
            <source>Zh Vopr Neirokhir Im N N Burdenko</source>
            <year>2018</year>
            <volume>82</volume>
            <issue>4</issue>
            <fpage>87</fpage>
            <page-range>87-96</page-range>
            <pub-id pub-id-type="pmid">30137042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ring</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Modesitt</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Current and future role of genetic screening in&#x000a0;gynecologic malignancies.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>217</volume>
            <issue>5</issue>
            <fpage>512</fpage>
            <page-range>512-521</page-range>
            <pub-id pub-id-type="pmid">28411145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McBride</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ballinger</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Schlub</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tattersall</surname>
                <given-names>MHN</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eeles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Killick</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Shanley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?</article-title>
            <source>Fam Cancer</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>423</fpage>
            <page-range>423-432</page-range>
            <pub-id pub-id-type="pmid">28124295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24243.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bester</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sabatello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Karnebeek</surname>
                <given-names>CDM</given-names>
              </name>
              <name>
                <surname>Lantos</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Please Test My Child for a Cancer Gene, but Don't Tell Her.</article-title>
            <source>Pediatrics</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>141</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29535250</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
